News

CV6 to Present Details of CV6-168 at Molecular Targets and Cancer Therapeutics Symposium  

25th September 2018

Belfast, UK. 25 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, today announced they would be presenting details on CV6-168, a novel anticancer therapeutic at the 30th EORTC/AACR/NCI Molecular Targets and Cancer Therapeutics Symposium in Dublin, Ireland on 16th of November 2018. The abstract […]

Read More

CV6 CEO Presents at Prestigious Heidelberger Symposium on Cancer Research

18th September 2018

Belfast, U.K. – 18 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, announced today that Dr. Robert Ladner, CEO and Founder, was invited to present the Company’s ground-breaking research that led to the development of the novel dUTPase inhibitor and clinical drug […]

Read More

CV6 CEO Speaks at Patrick Johnston QUB Memorial Symposium

18th May 2018

Belfast, UK. 17 May, 2018. Robert Ladner, CEO and Founder of CV6 Therapeutics Ltd (CV6), paid tribute today to Professor Patrick G. Johnston at a memorial symposium hosted by Queen’s University Belfast to honour and celebrate the life and accomplishments of “A Leader and Innovator in Cancer Research and Treatment”. Patrick, or ‘Paddy’ to those who […]

Read More

CV6 Therapeutics Strengthens Scientific Advisory Board with Recent Appointments

17th May 2018

Belfast, U.K. – May 17, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of three new members to their Scientific Advisory Board. Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, UK. […]

Read More

CV6 Therapeutics Appoints Richard Milliken as Board Chairman

19th March 2018

Belfast, U.K. – March 19, 2018.  CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Richard Milliken, CA as Chairman of the Board of Directors. “We are pleased to welcome Richard as our Board Chairman, his extensive experience […]

Read More

CV6 Therapeutics Appoints Chris Rivera to Board

17th March 2018

Belfast, U.K. – April 19, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Chris Riviera to the Board of Directors. “We are pleased to welcome Chris to our Board. Chris brings extensive experience in the pharmaceutical […]

Read More

New Investor CV6 Partners with QUB in Major Cancer R&D Project

24th May 2016

With support from Invest Northern Ireland, California based CV6 Therapeutics Ltd has chosen to partner with the Centre for Cancer Research and Cell Biology at Queen’s University, Belfast for a highly innovative R&D project.

Read More